Fresenius Medical Care AG & Co. KGaA

$ 40.70 -1.36 %

Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.

CEO: Helen Giza - https://www.freseniusmedicalcare.com

Price objectif

-

Recommandation

Hold

DCF

$ 106.35

Loading data...

FME.DE vs S&P500

Loading data...

No data available.

Quick ratio

0.86

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

12.45

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

3.27

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

7.16 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

5.76 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.36

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.83

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

6.49

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

44.71 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
1.81 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.18 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.35 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.